IL149176A0 - Therapeutic use - Google Patents
Therapeutic useInfo
- Publication number
- IL149176A0 IL149176A0 IL14917600A IL14917600A IL149176A0 IL 149176 A0 IL149176 A0 IL 149176A0 IL 14917600 A IL14917600 A IL 14917600A IL 14917600 A IL14917600 A IL 14917600A IL 149176 A0 IL149176 A0 IL 149176A0
- Authority
- IL
- Israel
- Prior art keywords
- therapeutic use
- patient
- chemoprevention
- onset
- effective amount
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000002113 chemopreventative effect Effects 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 208000030776 invasive breast carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9925958.2A GB9925958D0 (en) | 1999-11-02 | 1999-11-02 | Therapeutic use |
PCT/GB2000/004190 WO2001032155A2 (en) | 1999-11-02 | 2000-11-01 | Use of egfr tyrosine kinase inhibitors for treating breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149176A0 true IL149176A0 (en) | 2002-11-10 |
Family
ID=10863835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14917600A IL149176A0 (en) | 1999-11-02 | 2000-11-01 | Therapeutic use |
Country Status (21)
Country | Link |
---|---|
US (1) | US7553815B1 (de) |
EP (1) | EP1272188B1 (de) |
JP (1) | JP2003513035A (de) |
KR (1) | KR100785359B1 (de) |
CN (1) | CN1197577C (de) |
AT (1) | ATE339957T1 (de) |
AU (1) | AU779190B2 (de) |
BR (1) | BR0015194A (de) |
CA (1) | CA2389411C (de) |
CY (1) | CY1106285T1 (de) |
DE (1) | DE60030889T2 (de) |
DK (1) | DK1272188T3 (de) |
ES (1) | ES2275556T3 (de) |
GB (1) | GB9925958D0 (de) |
IL (1) | IL149176A0 (de) |
MX (1) | MXPA02004272A (de) |
NO (1) | NO323206B1 (de) |
NZ (1) | NZ518696A (de) |
PT (1) | PT1272188E (de) |
WO (1) | WO2001032155A2 (de) |
ZA (1) | ZA200203431B (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101135233B1 (ko) | 2000-05-19 | 2012-04-12 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
EP1441736A2 (de) * | 2001-10-29 | 2004-08-04 | Novartis AG | Verwendung von 7h-pyrrolo[2,3-d]pyrimidinderivaten in der behandlung solider tumore |
SI1450799T1 (sl) * | 2001-12-03 | 2007-02-28 | Bayer Pharmaceuticals Corp | Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
BR0311814A (pt) * | 2002-06-05 | 2005-03-15 | Cedars Sinai Medical Center | Método de tratar câncer empregando inibidores de cinase |
US20070059785A1 (en) * | 2003-08-15 | 2007-03-15 | Smithkline Beecham Corporation | Biomarkers in cancer |
DE602004004553T2 (de) | 2003-09-19 | 2007-10-25 | Astrazeneca Ab | Chinazolinderivate |
WO2005039588A2 (en) * | 2003-10-22 | 2005-05-06 | Novartis Ag | Methods for determining the risk of developing liver and lung toxicity |
US7701341B2 (en) * | 2004-09-01 | 2010-04-20 | Microsoft Corporation | Device service provider interface |
TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
ES2440481T3 (es) | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
WO2007091622A1 (ja) | 2006-02-09 | 2007-08-16 | Daiichi Sankyo Company, Limited | 抗癌医薬組成物 |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
MX2011009498A (es) | 2009-03-11 | 2011-10-14 | Ardea Biosciences Inc | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos. |
CN104447995A (zh) | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
EP2435071A1 (de) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulatoren für den her2-signalweg bei her2-exprimierenden patienten mit magenkrebs |
CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (de) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispezifische moleküle |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
EP2788500A1 (de) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identifizierung von non-respondern auf her2-inhibitoren |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5795910A (en) * | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
WO1996030347A1 (en) * | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
ES2203642T3 (es) * | 1995-06-07 | 2004-04-16 | Pfizer Inc. | Derivados de pirimidina heterociclicos con anillos condensados. |
DK0836605T3 (da) * | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
CN1314917A (zh) * | 1998-05-15 | 2001-09-26 | 伊姆克罗尼系统公司 | 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤 |
EP2059902B1 (de) | 2006-08-28 | 2010-04-07 | Koninklijke Philips Electronics N.V. | Verfahren und vorrichtung zur bilderweiterung |
-
1999
- 1999-11-02 GB GBGB9925958.2A patent/GB9925958D0/en not_active Ceased
-
2000
- 2000-11-01 CN CNB00815290XA patent/CN1197577C/zh not_active Expired - Fee Related
- 2000-11-01 BR BR0015194-7A patent/BR0015194A/pt not_active Application Discontinuation
- 2000-11-01 IL IL14917600A patent/IL149176A0/xx not_active IP Right Cessation
- 2000-11-01 JP JP2001534360A patent/JP2003513035A/ja active Pending
- 2000-11-01 AT AT00973002T patent/ATE339957T1/de not_active IP Right Cessation
- 2000-11-01 MX MXPA02004272A patent/MXPA02004272A/es active IP Right Grant
- 2000-11-01 EP EP00973002A patent/EP1272188B1/de not_active Expired - Lifetime
- 2000-11-01 AU AU11559/01A patent/AU779190B2/en not_active Ceased
- 2000-11-01 DE DE60030889T patent/DE60030889T2/de not_active Expired - Lifetime
- 2000-11-01 NZ NZ518696A patent/NZ518696A/xx not_active IP Right Cessation
- 2000-11-01 CA CA002389411A patent/CA2389411C/en not_active Expired - Fee Related
- 2000-11-01 KR KR1020027005551A patent/KR100785359B1/ko not_active IP Right Cessation
- 2000-11-01 WO PCT/GB2000/004190 patent/WO2001032155A2/en active IP Right Grant
- 2000-11-01 DK DK00973002T patent/DK1272188T3/da active
- 2000-11-01 ES ES00973002T patent/ES2275556T3/es not_active Expired - Lifetime
- 2000-11-01 US US10/111,390 patent/US7553815B1/en not_active Expired - Fee Related
- 2000-11-01 PT PT00973002T patent/PT1272188E/pt unknown
-
2002
- 2002-04-30 NO NO20022065A patent/NO323206B1/no not_active IP Right Cessation
- 2002-04-30 ZA ZA200203431A patent/ZA200203431B/xx unknown
-
2006
- 2006-12-11 CY CY20061101772T patent/CY1106285T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60030889T2 (de) | 2007-04-05 |
DK1272188T3 (da) | 2007-01-29 |
AU1155901A (en) | 2001-05-14 |
GB9925958D0 (en) | 1999-12-29 |
JP2003513035A (ja) | 2003-04-08 |
US7553815B1 (en) | 2009-06-30 |
PT1272188E (pt) | 2007-01-31 |
ES2275556T3 (es) | 2007-06-16 |
CA2389411A1 (en) | 2001-05-10 |
KR100785359B1 (ko) | 2007-12-18 |
WO2001032155A3 (en) | 2002-05-10 |
ZA200203431B (en) | 2003-02-26 |
MXPA02004272A (es) | 2003-08-20 |
NO20022065L (no) | 2002-06-24 |
KR20020064306A (ko) | 2002-08-07 |
CN1197577C (zh) | 2005-04-20 |
NO20022065D0 (no) | 2002-04-30 |
AU779190B2 (en) | 2005-01-13 |
EP1272188B1 (de) | 2006-09-20 |
CA2389411C (en) | 2009-09-01 |
EP1272188A2 (de) | 2003-01-08 |
NO323206B1 (no) | 2007-01-22 |
DE60030889D1 (de) | 2006-11-02 |
CN1387437A (zh) | 2002-12-25 |
BR0015194A (pt) | 2002-06-18 |
NZ518696A (en) | 2004-12-24 |
CY1106285T1 (el) | 2011-10-12 |
WO2001032155A2 (en) | 2001-05-10 |
ATE339957T1 (de) | 2006-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL149176A0 (en) | Therapeutic use | |
TR200201442T2 (tr) | Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı. | |
GEP20094798B (en) | (s,s)-reboxetine for treating chronic pain | |
EG25822A (en) | Quinolinyl-pyrrolopyrazoles | |
YU30004A (sh) | Upotreba flibanserina u lečenju seksualnih poremećaja | |
AU2003267203A8 (en) | Method for administering thermotherapy to prevent the growth of tumors | |
MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
MXPA00011248A (es) | Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento. | |
PL365244A1 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
MY164077A (en) | Compositions and uses of et743 for treating cancer | |
MX2007006927A (es) | Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer. | |
HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
GB0020504D0 (en) | Therapeutic method | |
AU5574001A (en) | Method for treatment of tumors using photodynamic therapy | |
PL366066A1 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
AU2001236529A1 (en) | Combination therapy for cancer | |
MD1569G2 (ro) | Metodă de tratament al cancerului mamar în perioada preoperatorie | |
IL159770A0 (en) | Calcium salts with cytotoxic activity | |
CY1109852T1 (el) | Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη | |
AU5434899A (en) | Cancer treatment | |
AU2001240885A1 (en) | Use of glucosylceramide synthesis inhibitors in brain cancer therapy | |
WO2000033823A3 (en) | Methods of using temozolomide in the treatment of cancers | |
IL164092A0 (en) | The use of devazepide as analgesic agent | |
UA28928A (uk) | Спосіб лікування гнійно-запальних захворювань м'яких тканин | |
UA34376A (uk) | Спосіб профілактики і корекції психосоматичних розладів у хворих при операціях з приводу рака молочної залози |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |